At the Champalimaud Colorectal Cancer Conference, last February, Gina Brown, from the Imperial College London, questioned the validity of the current staging strategy for colon cancer. Indeed, research shows that lymph nodes are not the main culprit in colon cancer spread, and can actually be a sign that the patient’s immune system is fighting back. 

Coordinated by Professor Ana Santos Almeida, principal investigator of a translational laboratory at the GIMM Foundation - Gulbenkian Institute for Molecular Medicine (GIMM-CARE), this study will take place at the Champalimaud Foundation, in collaboration with Dr. José Azevedo, surgeon of the Colorectal Cancer Group of the Digestive Unit of the Champalimaud Clinical Center, and at the Hospital de Santa Maria, with the participation of oncologists Professor Luís Costa and Dr. André Mansinho.

Developed by an international consortium of 117 experts in legal, ethical, clinical, and AI domains—and featuring Champalimaud Foundation (CF) Principal Investigator Nikolas Papanikolaou—the framework provides a detailed roadmap for creating trustworthy medical AI, from the earliest design stages all the way through clinical deployment and monitoring.

It all began with a little theatre play.

Three women working in  neuroscience walk into the stage. They have to decide what will be the topic of the next Ar Event. After some discussion, they settle on the theatre. How does neuroscience explain what happens when people watch actors perform?, they want to know. So they put their white labcoats on to better think scientifically. 

Each year, the European Association for the Study of Obesity (EASO) and the Novo Nordisk Foundation, honours exceptional research contributions that enhance our understanding of obesity, its causes, complications, prevention, and management. 

A new study from researchers at the Champalimaud Foundation (CF) investigated whether artificial intelligence (AI) could analyse MRI scans to reliably tell which cancers are less aggressive and which pose a greater risk. While AI showed promise, its accuracy varied significantly depending on the MRI scanner’s brand.

The Champalimaud Foundation has always been at the intersection of cutting-edge science, and exceptional care. 

Specialising in cutting-edge cancer treatment, neuropsychiatry, and experimental clinical research, the Champalimaud Clinical Centre is committed to advancing personalised medicine through groundbreaking research, merging advanced technology with human-centred care.

Watch the video to see how the Champalimaud Foundation has been transforming healthcare and improving lives for the past 20 years—and how we’ll continue to do so in the future.

An international team, co-led by Adriana Sánchez-Danés, principal investigator of the Cancer and Stem Cell Biology Lab at the Champalimaud Foundation, in Lisbon, has shown for the first time the important role of Survivin – a protein that has key roles in regulating cell division and inhibiting apoptosis (programmed cell death) – in the initiation and formation of a basal cell carcinoma, the most common human skin cancer. Their results have now been published in the print edition of January 8, 2025, of the journal Cell Discovery.

An international team of scientists, including a principal investigator in neuroscience from the Champalimaud Foundation, in Lisbon, has analysed the way expert London taxi drivers plan their route in advance every time they pick up passengers. It is the first time a study about human planning has been performed in a real-world, large-scale environment. Their results are published today (23rd of January) in the Proceedings of the National Academy of Sciences. 

Over the past decade, interest in psychedelics—including psilocybin, LSD, and MDMA—as treatments for psychiatric disorders has grown exponentially among scientists, mental health professionals, the media, and the public.